source
- FDA sends warning letters to Sanofi and Viatris over misleading product claimsThe FDA’s Office of Prescription Drug Promotion issued untitled warning letters to Sanofi and Viatris after reviewing promotional materials that the agency deemed misleading. The letters cite spec…
- Celldex halts skin disease program after barzolvolimab fails phase 2 trialCelldex Therapeutics announced it is discontinuing development of its anti‑KIT antibody barzolvolimab for chronic skin disorders after the drug failed to meet its primary endpoint in a phase 2 stud…